8-amino-3,4-dihydro-4,6-dimethyl-2H-pyridazino<4,5-b>-1,4-oxazin-5(6H)-one | 82412-95-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 8-amino-3,4-dihydro-4,6-dimethyl-2H-pyridazino<4,5-b>-1,4-oxazin-5(6H)-one
• 英文别名: 8-Amino-4,6-dimethyl-2,3-dihydropyridazino[4,5-b][1,4]oxazin-5-one
• CAS: 82412-95-1
• 化学式: C₈H₁₂N₄O₂
• 分子量: 196.209
• InChiKey: ZFUQPYLVHMREAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  71.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4,5-dichloro-2-methyl-6-nitro-3(2H)-pyridazinone 在 sodium ethanolate 作用下， 以 乙醇 、 水 、 溶剂黄146 为溶剂， 反应 8.0h， 生成 8-amino-3,4-dihydro-4,6-dimethyl-2H-pyridazino<4,5-b>-1,4-oxazin-5(6H)-one
  参考文献：
  名称：

  Synthesis and biological activity of pyridazinooxazines.

  摘要：

  4-氯-5-(2-羟基乙基氨基)-3 (2H)-吡嗪酮在碱处理后被转化为新型的融合环化合物，3, 4-二氢-2H-吡嗪[4, 5-b]-1, 4-氧杂啉-8 (7H)-酮。当羟基乙基氨基团中的氮原子或3 (2H)-吡嗪酮环的2位有剩余氢时，环闭合反应不会发生。3, 4-二氢-2H-吡嗪[4, 5-b]-1, 4-氧杂啉也通过相应前体合成。前体中的C-6氨基团对以上提到的环形成并没有影响，但当氨基团被重氮化时，环形成以不同的方式进行，涉及C-6重氮基团作为离去基团，形成另一个环系，6, 7-二氢-2H-吡嗪[3, 4-b]-[1, 4]氧杂啉-3 (5H)-酮。在C-6硝基基团的前体案例中也观察到了类似现象：环化发生，涉及硝基基团的消除，从而形成融合环产物。该方法被应用于三环杂环的形成，2H-吡嗪[3, 4-b][1, 4]苯氧杂啉-3 (5H)-酮。通过这种方法获得的一些化合物在动物模型中显示出强效的镇痛和显著的抗炎活性。

  DOI：

  10.1248/cpb.30.832

文献信息

• CHROMAN DERIVATIVE AND MEDICINAL USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：EP0677519A1

  公开（公告）日：1995-10-18

  A chroman derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, and a medicinal use thereof, wherein R¹ is cyano, nitro, trihalomethyl, trihalomethoxy or halogen; R² is lower alkoxyalkyl, aryloxyalkyl or dialkoxyalkyl; R³ is lower alkoxyalkyl or aryloxyalkyl; R⁴ is hydroxy, formyloxy or lower alkanoyloxy; X is N-H which may be substituted by lower alkyl, oxygen, sulfur or a single bond; Y is a residue of an aromatic or heterocyclic ring which may be substituted. The compound and pharmaceutically acceptable salt thereof have a prominent selective coronary vasodilator activity while having a minimized hypotensive effect. Therefore, they can selectively increase the coronary blood flow volume without the fear of causing sudden hypotension causative of tachycardia which adversely affects the heart, and hence are useful as a coronary vasodilator, in particular, as a preventive or remedy for cardiovascular disturbance such as angina pectoris or cardiac failure.

  一种由通式(I)代表的色烷衍生物、其药学上可接受的盐及其药用方法，其中 R¹是氰基、硝基、三卤甲基、三卤甲氧基或卤素；R²是低级烷氧基烷基、芳氧基烷基或二烷氧基烷基；R³ 是低级烷氧基烷基或芳氧基烷基；R⁴ 是羟基、甲酰氧基或低级烷酰氧基；X 是可被低级烷基、氧、硫或单键取代的 N-H；Y 是可被取代的芳环或杂环的残基。该化合物及其药学上可接受的盐具有突出的选择性冠状动脉血管扩张活性，同时具有最小的降压作用。因此，它们可以选择性地增加冠状动脉血流量，而不必担心引起突发性低血压导致心动过速，从而对心脏产生不利影响，因此可用作冠状动脉血管扩张剂，特别是作为心绞痛或心力衰竭等心血管疾病的预防或治疗药物。
• MATSUO, TOSHIYASU;TSUKAMOTO, YOSHITSUGU;TAKAGI, TAKASHI;SATO, MAKOTO, CHEM. AND PHARM. BULL., 1982, 30, N 3, 832-842
  作者：MATSUO, TOSHIYASU、TSUKAMOTO, YOSHITSUGU、TAKAGI, TAKASHI、SATO, MAKOTO

  DOI：——

  日期：——
• US5719155A
  申请人：——

  公开号：US5719155A

  公开（公告）日：1998-02-17
• Synthesis and biological activity of pyridazinooxazines.
  作者：TOSHIYASU MATSUO、YOSHITSUGU TSUKAMOTO、TAKASHI TAKAGI、MAKOTO SATO

  DOI：10.1248/cpb.30.832

  日期：——

  4-Chloro-5-(2-hydroxyethylamino)-3 (2H)-pyridazinones were converted upon treatment with base to novel fused ring compounds, 3, 4-dihydro-2H-pyridazino [4, 5-b]-1, 4-oxazin-8 (7H)-ones. When a nitrogen atom in the hydroxyethylamino group or at the 2-position of the 3 (2H)-pyridazinone ring had a remaining hydrogen, the ring closure reaction did not occur. 3, 4-Dihydro-2H-pyridazino [4, 5-b]-1, 4-oxazine was similarly synthesized from corresponding precursor. The presence of a C-6 amino group in the precursor did not affect the ring formation mentioned above, but when the amino group was diazotized, ring formation took place in a different fashion, involving the C-6 diazonium moiety as a leaving group, to give another ring system, 6, 7-dihydro-2H-pyridazino [3, 4-b]-[1, 4] oxazin-3 (5H)-one. Similar phenomena were observed in the cases of precursors having a C-6 nitro group : cyclization occurred involving the elimination of the nitro group to give fused ring products. The method was applied to the formation of a tricyclic heterocycle, 2H-pyridazino [3, 4-b] [1, 4] benzoxazin-3 (5H)-one. Some compounds thus obtained were found to have potent analgesic and significant anti-inflammatory activities in animal models.

  4-氯-5-(2-羟基乙基氨基)-3 (2H)-吡嗪酮在碱处理后被转化为新型的融合环化合物，3, 4-二氢-2H-吡嗪[4, 5-b]-1, 4-氧杂啉-8 (7H)-酮。当羟基乙基氨基团中的氮原子或3 (2H)-吡嗪酮环的2位有剩余氢时，环闭合反应不会发生。3, 4-二氢-2H-吡嗪[4, 5-b]-1, 4-氧杂啉也通过相应前体合成。前体中的C-6氨基团对以上提到的环形成并没有影响，但当氨基团被重氮化时，环形成以不同的方式进行，涉及C-6重氮基团作为离去基团，形成另一个环系，6, 7-二氢-2H-吡嗪[3, 4-b]-[1, 4]氧杂啉-3 (5H)-酮。在C-6硝基基团的前体案例中也观察到了类似现象：环化发生，涉及硝基基团的消除，从而形成融合环产物。该方法被应用于三环杂环的形成，2H-吡嗪[3, 4-b][1, 4]苯氧杂啉-3 (5H)-酮。通过这种方法获得的一些化合物在动物模型中显示出强效的镇痛和显著的抗炎活性。